Pharmaceuticals Analyst, Jefferies
Appears in 1 story
Tracking Hibsago's commercial prospects after approval
The Food and Drug Administration approved Hibsago on October 20, the first drug shown to clear chronic hepatitis B without lifelong treatment. In two late-stage trials, about one in five patients who took it reached undetectable virus levels and stayed off antiviral drugs for at least six months.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
